These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 9884816)

  • 1. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.
    Touw DJ; Vinks AA; Mouton JW; Horrevorts AM
    Clin Pharmacokinet; 1998 Dec; 35(6):437-59. PubMed ID: 9884816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations.
    Lindsay CA; Bosso JA
    Clin Pharmacokinet; 1993 Jun; 24(6):496-506. PubMed ID: 8513651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.
    Roberts JA; Lipman J
    Clin Pharmacokinet; 2006; 45(8):755-73. PubMed ID: 16884316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?
    Tod MM; Padoin C; Petitjean O
    Clin Pharmacokinet; 2001; 40(11):803-14. PubMed ID: 11735603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis.
    Santos RP; Prestidge CB; Brown ME; Urbancyzk B; Murphey DK; Salvatore CM; Jafri HS; McCracken GH; Ahmad N; Sanchez PJ; Siegel JD
    Pediatr Pulmonol; 2009 Feb; 44(2):148-54. PubMed ID: 19137597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose treatment with antibiotics in cystic fibrosis--a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF-patients.
    Sörgel F; Stephan U; Wiesemann HG; Gottschalk B; Stehr C; Rey M; Böwing HB; Dominick HC; Geldmacher von Mallinckrodt M
    Infection; 1987; 15(5):385-96. PubMed ID: 3319914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug disposition in cystic fibrosis.
    Rey E; Tréluyer JM; Pons G
    Clin Pharmacokinet; 1998 Oct; 35(4):313-29. PubMed ID: 9812180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of antimicrobial drugs in cystic fibrosis. Aminoglycoside antibiotics.
    Horrevorts AM; Driessen OM; Michel MF; Kerrebijn KF
    Chest; 1988 Aug; 94(2 Suppl):120S-125S. PubMed ID: 3293937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis.
    Illamola SM; Huynh HQ; Liu X; Bhakta ZN; Sherwin CM; Liou TG; Carveth H; Young DC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis.
    Touw DJ
    Pharm World Sci; 1998 Aug; 20(4):149-60. PubMed ID: 9762727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.
    Slavik RS; Jewesson PJ
    Clin Pharmacokinet; 2003; 42(9):793-817. PubMed ID: 12882587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.
    Bearden DT; Rodvold KA
    Clin Pharmacokinet; 2000 May; 38(5):415-26. PubMed ID: 10843460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivering antibacterials to the lungs: considerations for optimizing outcomes.
    Cazzola M; Blasi F; Terzano C; Matera MG; Marsico SA
    Am J Respir Med; 2002; 1(4):261-72. PubMed ID: 14720046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.
    Magréault S; Roy C; Launay M; Sermet-Gaudelus I; Jullien V
    Clin Pharmacokinet; 2021 Apr; 60(4):409-445. PubMed ID: 33486720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction to pharmacokinetics: aminoglycosides in cystic fibrosis as a prototype.
    Kearns GL; Trang JM
    J Pediatr; 1986 May; 108(5 Pt 2):847-53. PubMed ID: 3517272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
    Prescott WA
    Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of antimicrobial therapy in surgery.
    DiPiro JT; Edmiston CE; Bohnen JM
    Am J Surg; 1996 Jun; 171(6):615-22. PubMed ID: 8678212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of antibiotics in cystic fibrosis.
    Akkerman-Nijland AM; Akkerman OW; Grasmeijer F; Hagedoorn P; Frijlink HW; Rottier BL; Koppelman GH; Touw DJ
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):53-68. PubMed ID: 33213220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.